tHEORetically Speaking

In this episode of Theoretically Speaking, Paige McGarry interviews David W. Miller, CEO of Genesis Research Group, discussing the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.

David W. Miller discusses how Genesis Research Group addresses these challenges, including the importance of demonstrating value early in development, the role of real-world evidence in supporting biotechs, and how to navigate uncertainty in the biotech landscape. Additionally, strategies for effective data collection are introduced, while emphasizing the need for flexibility and adaptability in the ever-evolving life sciences sector.  Genesis Research Group's Flexible Integrated Team (FIT) model is also discussed as an adaptable and fit-for-purpose program to support biotechs, ensuring development and launch are optimized, regardless of size, resources, and specific needs. Representing a true paradigm shift in strategic partnerships, David explains how the Genesis team is able to adapt their extensive global expertise in areas such as pricing, real-world evidence, HEOR, and market access as they support emerging biotechs to ensure commercial success.

For more information or to access other resources, click here.

This episode features Matt McLoughlin, Senior Vice President of Compliance and Categories at Scientist.com. With 25 years in pharma R&D and Procurement, Matt has enhanced outsourcing for biopharma companies, focusing on speed, efficiency, and compliance. His expertise in regulated industries extends to RWE, HEOR, and Market Access, transforming access to external services to boost innovation while cutting costs and project timelines.

To stay connected with us, visit our LinkedIn page and subscribe to our newsletter!

Learn more about Scientist.com and how they can help with planning your book of work here: https://www.healtheconomics.com/5-key-questions-to-ask-before-you-launch-a-value-evidence-plan

Welcome to INsights & OUTcomes, the newest podcast on tHEORetically Speaking from HealthEconomics.com, where we sit down with the leading professionals in HEOR, RWE, and market access, the experts shaping the future of healthcare decisions.

This episode features Catherine Bacon, founder of FingerPost Consulting in Manchester. She has more than 15 years of experience in market access, predominantly as a consultant. Driven by a passion for addressing the challenges of high-cost, innovative treatments, she is committed to ensuring these therapies reach the right patients at the right time and price.

To stay connected with us, visit our LinkedIn page and subscribe to our newsletter!

Learn more about FingerPost Consulting:
https://healtheconomics.com/partner/fingerpost-consulting-ltd/

Welcome to INsights & OUTcomes, the newest podcast on tHEORetically Speaking from HealthEconomics.com, where we sit down with the leading professionals in HEOR, RWE, and market access, the experts shaping the future of healthcare decisions.

This episode features Dr. Vernon Schabert, Founder of Epilogix. Vernon is an internationally-recognized health economist and pharmacoepidemiologist and has nearly 30 years of HEOR, RWD, and RWE industry experience.

To stay connected with us, visit our LinkedIn page and subscribe to our newsletter!

Learn more about Epilogix: https://healtheconomics.com/suppliers/epilogix-llc/

Welcome to INsights & OUTcomes, the newest podcast on tHEORetically Speaking from HealthEconomics.com, where we sit down with the leading professionals in HEOR, RWE, and market access, the experts shaping the future of healthcare decisions.

This episode features Rosa Willock, a Senior Consultant at Decisive Consulting. She leads the RWE function at Decisive Consulting, which includes helping clients to identify and address gaps in their evidence packages, and more recently, helping them to plan for the new EUHTAR.

To stay connected with us, visit our LinkedIn page and subscribe to our newsletter!

Learn more about Decisive Consulting: https://healtheconomics.com/suppliers/decisive-consulting/

Welcome to INsights & OUTcomes, the newest podcast on tHEORetically speaking from HealthEconomics.com, where we sit down with the leading professionals in HEOR, RWE, and market access, the experts shaping the future of healthcare decisions.

This episode features Chris O'Neill, founder and CEO of Bosun MA. He has has over 20 years’ experience developing and delivering value and Market Access solutions for Pharma clients at a global and regional level.

BOSUN MA has over 20 years of expertise in payer understanding, and they use the latest AI technologies to help align clinical outcomes and Payer Need. Bosun MA is a leading architect of AI SaaS tools which enable clients to develop value messages that are underpinned by clinical evidence and which can be tested systematically against the value drivers in multiple geographies and Payer environments. They work globally in all major therapeutic areas and have a rich experience in developing value strategies across all development stages: helping to drive investment decisions and launch programs.

Join us for INsights & OUTcomes where we sit down with the leading professionals in HEOR, RWE & RWD, and Market Access, the experts shaping the future of healthcare decisions.

We'll dive into their careers, their passions, and the biggest trends in health economics today. We break down the numbers, challenge assumptions, and uncover what really drives healthcare decision making.

Subscribe now!

This episode of tHEORetically Speaking features Jeffrey Brown, PhD and Matvey Palchuk, MD, MS, FAMIA of TriNetX, who discuss the rise of RWD and its role in revolutionizing healthcare research, and how the TriNetX team approaches data quality to ensure research-ready RWD.

With increasing use of real-world data (RWD) throughout the drug development cycle — from initial discovery through to market approval and post-market monitoring — comes increasing scrutiny about the quality of the data.

To watch the full interview, click here.

This episode of tHEORetically Speaking is the fourth podcast in Panalgo’s ‘Between Two Scientists’, featuring host Meg Richards, PhD, MPH, who sits down with Panalgo’s VP of Medical Affairs, Dr. Mark Friedman, to discuss balancing the health needs of a pregnant woman and her developing baby, and how RWD can help.

Have a listen to the third ‘Between Two Scientists’ podcast, where Norstella’s General Manager of RWD, Ted Search, highlighted the challenges of incorporating new types of unstructured real-world data with structured data.

For more information or to access other resources, click here. 

In this episode of tHEORetically speaking, Dr. Joseph Zabinksi, VP and Head of Commercial Strategy and AI at OM1, explains how AI-powered digital phenotyping can enhance our understanding of patients' experiences and inform access, treatment, and condition management.

Real-world data provides an opportunity to understand what happens to patients, but there are limitations to the insights we can generate using traditional analysis techniques alone. At OM1, our PhenOM technology uses AI to isolate subtle signals in real-world data associated with outcomes we care about - diagnoses, treatment response, and future risks. The insights we derive integrate into our existing patient journeys to answer questions we couldn't without this technology, including who remains undiagnosed or misdiagnosed, and how patient subcohorts take different trajectories within the same broader condition.

To learn more, click here.